Venezuela (Bolivarian Republic of)
Tuberculosis profile
Population  2013 30 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.48 (0.47–0.48) 1.6 (1.6–1.6)
Mortality (HIV+TB only) 0.32 (0.24–0.42) 1.1 (0.78–1.4)
Prevalence  (includes HIV+TB) 15 (7.8–24) 49 (26–79)
Incidence  (includes HIV+TB) 10 (8.9–11) 33 (29–37)
Incidence (HIV+TB only) 1.1 (1–1.3) 3.7 (3.3–4.2)
Case detection, all forms (%) 65 (58–73)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.5 (0.1–1.3) 14 (7.6–22)
MDR-TB cases among notified pulmonary
TB cases
25 (5–65) 88 (49–140)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 3 538   284
Pulmonary, clinically diagnosed 1 496   64
Extrapulmonary 1 163   10
       
Total new and relapse 6 555    
Previously treated, excluding relapses 302    
Total cases notified 6 857    
Among 6 555 new and relapse cases:
461 (7%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 77 (2%) 210 (32%) 287
Laboratory-confirmed RR-/MDR-TB cases     41
Patients started on MDR-TB treatment     19
TB/HIV 2013 Number (%)
TB patients with known HIV status 5 001 (73)
HIV-positive TB patients 560 (11)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 106 (19)
HIV-positive TB patients on antiretroviral therapy (ART) 504 (90)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 82
Previously treated cases, excluding relapse, registered in 2012 72
HIV-positive TB cases, all types, registered in 2012 72
RR-/MDR-TB cases started on second-line treatment in 2011 57
XDR-TB cases started on second-line treatment in 2011 75
Laboratories 2013  
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 2.6
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 1
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-30 Data: www.who.int/tb/data